Figure 2.

TRIM45 inhibits glioma progression in vitro and in vivo. (a) Lysates of TRIM45-expressing and control U87 and LN229 cells were immunoblotted with anti-Flag antibody. β-Actin was used as a loading control. (c) Lysates of TRIM45 KO and control U87 and LN229 cells were immunoblotted with an anti-TRIM45 antibody. β-Actin was used as a loading control. (b and d) Growth curves were performed by plating a fixed number of cells in triplicate and counting cells at different time points. (e–h) Anchorage-independent growth assay of TRIM45-overexpressing (e and f) and TRIM45 KO (g and h) U87 and LN229 cells. Scale bars: 200 μm. (i–k) Xenograft tumors derived from LN229 cells transfected with TRIM45 or empty vector control lentivirus. Tumor growth (i), representative images of tumor growth (j) and the measured tumor weights (k) are presented. Each bar represents the mean±S.D. of three independent experiments. *P<0.05 and **P<0.01